share_log

石藥集團：內幕消息 - 石藥創新製藥股份有限公司截至2024年3月31日止3個月之主要財務資料

CSPC PHARMA: INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2024

Hong Kong Stock Exchange ·  Apr 22 21:32
Summary by Futu AI
石藥集團旗下子公司石藥創新製藥股份有限公司公佈2024年第一季度財務報告，顯示截至2024年3月31日止三個月的主要財務數據。報告期內，石藥創新營業收入較上年同期下降27.08%，至524,066,868.93元人民幣；歸屬於上市公司股東的淨利潤下降38.86%，至79,061,260.62元人民幣；而扣除非經常性損益後的淨利潤更下降56.44%。經營活動產生的現金流量淨額亦顯示出-429.29%的巨幅下降。總資產和歸屬於上市公司股東的所有者權益分別下降13.45%及增加1.00%。石藥創新指出，收入及利潤下降主要由於咖啡因產品價格下降及生物創新藥業務子公司巨石生物尚在研發階段，尚未貢獻收入及利潤。石藥集團於2024年4月23日發佈此公告，並提醒股東及公眾投資者注意。
石藥集團旗下子公司石藥創新製藥股份有限公司公佈2024年第一季度財務報告，顯示截至2024年3月31日止三個月的主要財務數據。報告期內，石藥創新營業收入較上年同期下降27.08%，至524,066,868.93元人民幣；歸屬於上市公司股東的淨利潤下降38.86%，至79,061,260.62元人民幣；而扣除非經常性損益後的淨利潤更下降56.44%。經營活動產生的現金流量淨額亦顯示出-429.29%的巨幅下降。總資產和歸屬於上市公司股東的所有者權益分別下降13.45%及增加1.00%。石藥創新指出，收入及利潤下降主要由於咖啡因產品價格下降及生物創新藥業務子公司巨石生物尚在研發階段，尚未貢獻收入及利潤。石藥集團於2024年4月23日發佈此公告，並提醒股東及公眾投資者注意。
Petropharmaceutical Innovative Pharmaceutical Co., Ltd., a subsidiary of the PDO Group, announced its first quarter financial report for 2024 showing key financial data for the three months ended 31 March 2024. DURING THE REPORTING PERIOD, PETROLEUM INNOVATION REVENUE DECREASED 27.08% TO RMB524,066,868.93 COMPARED TO THE SAME PERIOD LAST YEAR; NET PROFIT ATTRIBUTABLE TO SHAREHOLDERS OF LISTED COMPANIES DECREASED 38.86% TO RMB79,061,260.62; AND NET PROFIT AFTER NON-RECURRING LOSSES DECREASED 56.44%. The net cash flow generated by operating activities also showed a significant decrease of -429.29%. Total assets and shareholders' equity belonging to listed company shareholders decreased by 13.45% and increased by 1.00%, respectively. Petrol Innovation noted that the decline in revenue and profit was mainly due to lower caffeine product prices and Bio-Innovative Pharmaceuticals subsidiary StoneBios, which is still in the R&D phase, and has not contributed to revenue and profit. THE PETROLEUM GROUP ISSUED THIS ANNOUNCEMENT ON 23 APRIL 2024 AND REMINDS SHAREHOLDERS AND GENERAL INVESTORS TO THE ATTENTION OF SHAREHOLDERS AND PUBLIC INVESTORS.
Petropharmaceutical Innovative Pharmaceutical Co., Ltd., a subsidiary of the PDO Group, announced its first quarter financial report for 2024 showing key financial data for the three months ended 31 March 2024. DURING THE REPORTING PERIOD, PETROLEUM INNOVATION REVENUE DECREASED 27.08% TO RMB524,066,868.93 COMPARED TO THE SAME PERIOD LAST YEAR; NET PROFIT ATTRIBUTABLE TO SHAREHOLDERS OF LISTED COMPANIES DECREASED 38.86% TO RMB79,061,260.62; AND NET PROFIT AFTER NON-RECURRING LOSSES DECREASED 56.44%. The net cash flow generated by operating activities also showed a significant decrease of -429.29%. Total assets and shareholders' equity belonging to listed company shareholders decreased by 13.45% and increased by 1.00%, respectively. Petrol Innovation noted that the decline in revenue and profit was mainly due to lower caffeine product prices and Bio-Innovative Pharmaceuticals subsidiary StoneBios, which is still in the R&D phase, and has not contributed to revenue and profit. THE PETROLEUM GROUP ISSUED THIS ANNOUNCEMENT ON 23 APRIL 2024 AND REMINDS SHAREHOLDERS AND GENERAL INVESTORS TO THE ATTENTION OF SHAREHOLDERS AND PUBLIC INVESTORS.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.